An interventional study of Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide in Pancreatic Diseases, sponsored by Chengfeng Wang. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-01-16.
Sponsored by Chengfeng Wang · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Pancreatic Diseases with a site in China — 15 open to participants now, 15 under way, none of them phase 3. Pancreatic Diseases · China.
Among the 23 studies in Pancreatic Diseases with a site in China, this one is the 13th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2018, is one of 16 with no phase, and was the 5th registered.
184 studies on the registry are indexed under Pancreatic Diseases; 63 are open to participants now.
Browse Pancreatic Diseases studies →15 of the 23 studies in Pancreatic Diseases with a site in China are open now. Recruiting first, the newest first:
Changhai Hospital · Sites in China
Ages 18–75
Gang Chen · Sites in China
Ages 60+
The Third Xiangya Hospital of Central South University · Sites in China
Ages 18–80 · Healthy volunteers
Ruijin Hospital · Sites in China
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 43 Pancreatic Diseases studies recruiting now, 25 (58%) set no upper age limit and 4 (9%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 96 across 104 interventional studies indexed under Pancreatic Diseases.
Median enrollment 200 across the 18 interventional studies, 800 across the 5 observational. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 23 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Chengfeng Wang as lead sponsor.
Chengfeng Wang has 1 study filed under Pancreatic Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Pancreatic Diseases with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07023562Changhai HospitalThe 22G Trident Needle Combined With Different Aspiration Techniques for Endoscopic Ultrasound-guided Fine-needle Biopsy | 2027-05-26 |
| NCT07023549Changhai HospitalThe 22G Franseen Needle Combined With Different Aspiration Techniques for Endoscopic Ultrasound-guided Fine-needle Biopsy | 2027-05-31 |
| NCT06824909Ruijin HospitalEndoscopic Ultrasound-guided Fine-needle Aspiration of Solid Pancreatic Lesions With Rapid Staining of Cytological Smears Followed by Whole Slide Scanning and Artificial Intelligence Diagnosis: A Prospective, Multicenter Study. | 2027-05-31 |
| NCT07464392Changhai HospitalFMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis | 2027-07-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 23 studies in Pancreatic Diseases with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Effect of Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide on the Complications After Pancreatectomy. A Prospective, Multicenter Clinical Trial
The trial is funded by Cancer Foundation of China. The trial is prepared to be registered on the clinicaltrail.gov.
Quality assurance plan: every participant is enrolled or excluded by two practiced investigators. And two investigators participated in all steps of the trail, including the record of the data, and the investigators will compare the data. If the data is consistent, the investigators would record the data; if not, the data would be checked and decided by the two investigators. All the steps and data are site monitored and audited by the workers of research and financial department of National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences.
Data check: the investigators compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry. Source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources, including medical records and electronic case report forms.
Data dictionary that contains detailed descriptions of each variable used by the registry, including the source of the variable, coding information, and normal ranges if relevant.
Standard Operating Procedures to address registry operations and analysis activities, such as participants recruitment, data collection, data management, data analysis, reporting for adverse events, and change management. All registry operations would be done according to specific steps, and by two practiced investigators.
Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect. According to the formula to differ advantages and disadvantages, the investigators need at least 70 participants to take part in the trail.
The investigators can recruit about 150 participants according to previous experiences.
Plan for missing data: the investigators would collect as much data as possible, and the investigators exclude the participants who cannot cooperate on recruitment. And the investigators manage situations according to statistical principles where variables are reported as missing, unavailable, "non-reported," uninterpretable, or considered missing because of data inconsistency or out-of-range results.
Statistical analysis plan: Kaplan-Meier method would be used to analyze the difference of survival time between the two groups, and the local control rate of the two groups would be compared by chi square test. Statistical analyses would be performed by using IBM SPSS Statistics(version 20; IBM, Chicago, USA). The level of significance is defined as P \< 0.05.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide
Long-Period Octreotide 20mg one week before operation combine Short Period Octreotide 0.3mg during postoperative five days.
pancreatic fistula
Time frame: three week after operation
delayed gastric emptying
Time frame: three week after operation
intra-abdominal fluid collections
Time frame: three week after operation
wound infection
Time frame: three week after operation
Bile leak
Time frame: three week after operation
Abdominal bleeding
Time frame: three week after operation
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2018; primary completion for Jan 2019, 11 months later.
Of 32 interventional studies with no phase under Pancreatic Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's planned 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.